Semaglutide can rapidly reduce heart attacks and other serious cardiovascular complications in adults with overweight or ...

Novo Nordisk’s Wegovy (semaglutide injection) 2.4mg has demonstrated early protection against heart disease, according to new ...

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

New study finds weight loss jabs not only help tackle obesity but may significantly reduce alcohol use, offering wide health ...

GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening steatohepatitis.

Fatty liver disease, also called metabolic dysfunction-associated steatohepatitis (MASH), is a condition where fat ...

Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment ...

We expected miracles; what we got was a legal minefield. As GLP-1 drugs like Ozempic reshape bodies and bottom lines, a ...

Chances are, you haven’t heard of metabolic dysfunction–associated steatohepatitis (MASH)—but you’ve almost definitely heard ...

Q2 2025 Results Conference Call May 8, 2025 8:00 AM ETCompany ParticipantsSam Fisch - Executive Director, Investor Relations ...

Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track ...

Understand how semaglutide shows strong benefits in MASH treatment, improving liver health and reducing weight.